

Sophie Postel-Vinay (MD, Ph.D), is Physician Scientist at the Drug Development Department (where she is Senior Medical Oncologist) and U981 INSERM research unit (Group Leader) at Gustave Roussy.

She received her medical degree from the Université Paris XI in 2010, and joined the faculty in November 2013 after completion of her PhD performed at the Institute of Cancer Research (London), which focused on DNA repair and synthetic lethality. Specialized in Drug Development and early phase clinical trials, she completed her medical oncology residency training in Paris, and spent 18 months at the Royal Marsden Hospital of London at the Drug Development Unit. Dr Postel-Vinay is member of ESMO, AACR and ASCO. She was the head of the Phase 1 committee between 2020 and 2022, and is particularly interested in novel clinical trial designs and dose-definition in phase 1 trials.

Thanks to her Physician Scientist position, Dr Postel-Vinay also has a fundamental and translational research activity within the INSERM Unit 981. She obtained in 2018 the ATIP-Avenir "Young Group Leader" grant from INSERM, reinforced by an ERC StG in 2022, which allowed her to develop her own independent group. In 2019, she was granted the "Prix Irène Joliot-Curie" from the French Academy of Sciences for her scientific research work, and the "Prix Gallet et Breton" from the French Medicine Academy for her clinical research. Her current research activity focuses on chromatin remodeling and its interplay with DNA repair and immune modulation in solid tumors. Her research interests include DNA repair, chromatin remodeling, synthetic lethality, sarcoma, predictive biomarkers and drug development. As a clinician scientist, she endeavors to translate her laboratory results into clinical protocols, and has accordingly developed several early phase academic studies based on her research.